Review



mcm2 rbt-mcm2 antibody  (Bio SB Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Bio SB Inc mcm2 rbt-mcm2 antibody
    Mcm2 Rbt Mcm2 Antibody, supplied by Bio SB Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mcm2+rbt-mcm2+antibody/mcm2+rbt+mcm2+antibody/pm39924553-464-344-346
    Average 90 stars, based on 1 article reviews
    mcm2 rbt-mcm2 antibody - by Bioz Stars, 2026-10
    90/100 stars

    Images

    Related Articles

    Control:

    Article Title: CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities
    Article Snippet: The mIF panel consisted of the following antibodies (clone, company, and opal fluorophores): Cyclin D (SP4, Epredia, Opal 570), Cyclin E (EP435E, abcam, Opal 520), MCM2 (RBT-MCM2, Biosb, Opal Polaris 480), Pan Cytokeratin (AE1AE3, Agilent DAKO, Opal Polaris 780), pHH3 (Ser10, Millipore Sigma, Opal 620), pRB (Ser807/811, Cell Signaling, Opal 690).

    Article Title: Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle.
    Article Snippet: The MIF panel consisted of the following PHA-793887 Palbociclib Hesperadin Milciclib BMS-265246 Trametinib 0 20 40 60 80 100 0 20 40 60 80 100 ) Mn 052( 513X NI DMSO HCC1806 CCNE1 RB1 AMBRA1 DYRK1A PTEN -8 -6 -4 -2 0 2 4 6 8 10 0 5000 10000 15000 20000 N or m Z Rank_Synth HCC1806+Palbo (500 nM) CCNE1 CDK2 RB1 PTEN AMBRA1 DYRK1A -10 -5 0 5 10 15 0 5000 10000 15000 20000 Z mro N Rank_Synth MiaPaCa-2+Palbo (250 nM) Palbociclib Rapamycin BMS-265246 Barasertib SNS-032 Afatinib 0 20 40 60 80 100 120 0 20 40 60 80 100 120 IN X- ) Mn 0 01( 51 3 DMSO 1222 PHA-680632 Trametinib Palbociclib PD318088 PF-03814735 0 20 40 60 80 100 120 0 20 40 60 80 100 120 IN X- ) Mn 001( 513 DMSO 3226 20000 70000 120000 0 10 2 10 3 10 4 2N 4N 20000 70000 120000 0 10 1 10 2 10 3 10 4 2N 4N 20000 70000 120000 0 10 2 10 3 10 4 2N 4N 20000 70000 120000 0 10 1 10 2 10 3 10 4 2N 4N 20000 60000 100000 10 0 10 2 10 3 10 4 2N 4N 20000 60000 100000 0 10 1 10 2 10 3 10 4 2N 4N 20000 60000 100000 0 10 1 10 2 10 3 10 4 4N2N 20000 60000 100000 0 10 1 10 2 10 3 10 4 4N2N Palbo INX-315 Palbo+INX-315 PI Br dU -F IT C H C C 1806 M iaPaC a-2 DMSO - - + - - + + + - - + - - + + + Palbo (250 nM) INX-315 (250 nM) MiaPaCa-2-WT MiaPaCa-2-RB-del β Actin CDK1 Cyclin B1 Cyclin A pRB (S807/811) 40 35 55 55 100 Nature Communications | (2025) 16:1476 16 antibodies, cyclin A (Y193, abcam, 1/600, Opal 540), Cytokeratin (AE1/ AE3, Agilent DAKO, 1/300, Opal 480), Ki67 (SP6, abcam, 1/200, Opal 780), pRB ser807/811 (D20B12, Cell Signaling, 1/250, Opal 690), RB (4H1, Cell Signaling, 1/150, Opal 620) andMCM2 (RBT-MCM2, BioSB, 1/ 750, Opal 650).

    Recombinant:

    Article Title: CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities
    Article Snippet: The mIF panel consisted of the following antibodies (clone, company, and opal fluorophores): Cyclin D (SP4, Epredia, Opal 570), Cyclin E (EP435E, abcam, Opal 520), MCM2 (RBT-MCM2, Biosb, Opal Polaris 480), Pan Cytokeratin (AE1AE3, Agilent DAKO, Opal Polaris 780), pHH3 (Ser10, Millipore Sigma, Opal 620), pRB (Ser807/811, Cell Signaling, Opal 690).

    Article Title: Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle.
    Article Snippet: The MIF panel consisted of the following PHA-793887 Palbociclib Hesperadin Milciclib BMS-265246 Trametinib 0 20 40 60 80 100 0 20 40 60 80 100 ) Mn 052( 513X NI DMSO HCC1806 CCNE1 RB1 AMBRA1 DYRK1A PTEN -8 -6 -4 -2 0 2 4 6 8 10 0 5000 10000 15000 20000 N or m Z Rank_Synth HCC1806+Palbo (500 nM) CCNE1 CDK2 RB1 PTEN AMBRA1 DYRK1A -10 -5 0 5 10 15 0 5000 10000 15000 20000 Z mro N Rank_Synth MiaPaCa-2+Palbo (250 nM) Palbociclib Rapamycin BMS-265246 Barasertib SNS-032 Afatinib 0 20 40 60 80 100 120 0 20 40 60 80 100 120 IN X- ) Mn 0 01( 51 3 DMSO 1222 PHA-680632 Trametinib Palbociclib PD318088 PF-03814735 0 20 40 60 80 100 120 0 20 40 60 80 100 120 IN X- ) Mn 001( 513 DMSO 3226 20000 70000 120000 0 10 2 10 3 10 4 2N 4N 20000 70000 120000 0 10 1 10 2 10 3 10 4 2N 4N 20000 70000 120000 0 10 2 10 3 10 4 2N 4N 20000 70000 120000 0 10 1 10 2 10 3 10 4 2N 4N 20000 60000 100000 10 0 10 2 10 3 10 4 2N 4N 20000 60000 100000 0 10 1 10 2 10 3 10 4 2N 4N 20000 60000 100000 0 10 1 10 2 10 3 10 4 4N2N 20000 60000 100000 0 10 1 10 2 10 3 10 4 4N2N Palbo INX-315 Palbo+INX-315 PI Br dU -F IT C H C C 1806 M iaPaC a-2 DMSO - - + - - + + + - - + - - + + + Palbo (250 nM) INX-315 (250 nM) MiaPaCa-2-WT MiaPaCa-2-RB-del β Actin CDK1 Cyclin B1 Cyclin A pRB (S807/811) 40 35 55 55 100 Nature Communications | (2025) 16:1476 16 antibodies, cyclin A (Y193, abcam, 1/600, Opal 540), Cytokeratin (AE1/ AE3, Agilent DAKO, 1/300, Opal 480), Ki67 (SP6, abcam, 1/200, Opal 780), pRB ser807/811 (D20B12, Cell Signaling, 1/250, Opal 690), RB (4H1, Cell Signaling, 1/150, Opal 620) andMCM2 (RBT-MCM2, BioSB, 1/ 750, Opal 650).

    Chemiluminescent ELISA:

    Article Title: CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities
    Article Snippet: The mIF panel consisted of the following antibodies (clone, company, and opal fluorophores): Cyclin D (SP4, Epredia, Opal 570), Cyclin E (EP435E, abcam, Opal 520), MCM2 (RBT-MCM2, Biosb, Opal Polaris 480), Pan Cytokeratin (AE1AE3, Agilent DAKO, Opal Polaris 780), pHH3 (Ser10, Millipore Sigma, Opal 620), pRB (Ser807/811, Cell Signaling, Opal 690).

    Article Title: Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle.
    Article Snippet: The MIF panel consisted of the following PHA-793887 Palbociclib Hesperadin Milciclib BMS-265246 Trametinib 0 20 40 60 80 100 0 20 40 60 80 100 ) Mn 052( 513X NI DMSO HCC1806 CCNE1 RB1 AMBRA1 DYRK1A PTEN -8 -6 -4 -2 0 2 4 6 8 10 0 5000 10000 15000 20000 N or m Z Rank_Synth HCC1806+Palbo (500 nM) CCNE1 CDK2 RB1 PTEN AMBRA1 DYRK1A -10 -5 0 5 10 15 0 5000 10000 15000 20000 Z mro N Rank_Synth MiaPaCa-2+Palbo (250 nM) Palbociclib Rapamycin BMS-265246 Barasertib SNS-032 Afatinib 0 20 40 60 80 100 120 0 20 40 60 80 100 120 IN X- ) Mn 0 01( 51 3 DMSO 1222 PHA-680632 Trametinib Palbociclib PD318088 PF-03814735 0 20 40 60 80 100 120 0 20 40 60 80 100 120 IN X- ) Mn 001( 513 DMSO 3226 20000 70000 120000 0 10 2 10 3 10 4 2N 4N 20000 70000 120000 0 10 1 10 2 10 3 10 4 2N 4N 20000 70000 120000 0 10 2 10 3 10 4 2N 4N 20000 70000 120000 0 10 1 10 2 10 3 10 4 2N 4N 20000 60000 100000 10 0 10 2 10 3 10 4 2N 4N 20000 60000 100000 0 10 1 10 2 10 3 10 4 2N 4N 20000 60000 100000 0 10 1 10 2 10 3 10 4 4N2N 20000 60000 100000 0 10 1 10 2 10 3 10 4 4N2N Palbo INX-315 Palbo+INX-315 PI Br dU -F IT C H C C 1806 M iaPaC a-2 DMSO - - + - - + + + - - + - - + + + Palbo (250 nM) INX-315 (250 nM) MiaPaCa-2-WT MiaPaCa-2-RB-del β Actin CDK1 Cyclin B1 Cyclin A pRB (S807/811) 40 35 55 55 100 Nature Communications | (2025) 16:1476 16 antibodies, cyclin A (Y193, abcam, 1/600, Opal 540), Cytokeratin (AE1/ AE3, Agilent DAKO, 1/300, Opal 480), Ki67 (SP6, abcam, 1/200, Opal 780), pRB ser807/811 (D20B12, Cell Signaling, 1/250, Opal 690), RB (4H1, Cell Signaling, 1/150, Opal 620) andMCM2 (RBT-MCM2, BioSB, 1/ 750, Opal 650).

    BrdU Incorporation Assay:

    Article Title: CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities
    Article Snippet: The mIF panel consisted of the following antibodies (clone, company, and opal fluorophores): Cyclin D (SP4, Epredia, Opal 570), Cyclin E (EP435E, abcam, Opal 520), MCM2 (RBT-MCM2, Biosb, Opal Polaris 480), Pan Cytokeratin (AE1AE3, Agilent DAKO, Opal Polaris 780), pHH3 (Ser10, Millipore Sigma, Opal 620), pRB (Ser807/811, Cell Signaling, Opal 690).

    Article Title: Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle.
    Article Snippet: The MIF panel consisted of the following PHA-793887 Palbociclib Hesperadin Milciclib BMS-265246 Trametinib 0 20 40 60 80 100 0 20 40 60 80 100 ) Mn 052( 513X NI DMSO HCC1806 CCNE1 RB1 AMBRA1 DYRK1A PTEN -8 -6 -4 -2 0 2 4 6 8 10 0 5000 10000 15000 20000 N or m Z Rank_Synth HCC1806+Palbo (500 nM) CCNE1 CDK2 RB1 PTEN AMBRA1 DYRK1A -10 -5 0 5 10 15 0 5000 10000 15000 20000 Z mro N Rank_Synth MiaPaCa-2+Palbo (250 nM) Palbociclib Rapamycin BMS-265246 Barasertib SNS-032 Afatinib 0 20 40 60 80 100 120 0 20 40 60 80 100 120 IN X- ) Mn 0 01( 51 3 DMSO 1222 PHA-680632 Trametinib Palbociclib PD318088 PF-03814735 0 20 40 60 80 100 120 0 20 40 60 80 100 120 IN X- ) Mn 001( 513 DMSO 3226 20000 70000 120000 0 10 2 10 3 10 4 2N 4N 20000 70000 120000 0 10 1 10 2 10 3 10 4 2N 4N 20000 70000 120000 0 10 2 10 3 10 4 2N 4N 20000 70000 120000 0 10 1 10 2 10 3 10 4 2N 4N 20000 60000 100000 10 0 10 2 10 3 10 4 2N 4N 20000 60000 100000 0 10 1 10 2 10 3 10 4 2N 4N 20000 60000 100000 0 10 1 10 2 10 3 10 4 4N2N 20000 60000 100000 0 10 1 10 2 10 3 10 4 4N2N Palbo INX-315 Palbo+INX-315 PI Br dU -F IT C H C C 1806 M iaPaC a-2 DMSO - - + - - + + + - - + - - + + + Palbo (250 nM) INX-315 (250 nM) MiaPaCa-2-WT MiaPaCa-2-RB-del β Actin CDK1 Cyclin B1 Cyclin A pRB (S807/811) 40 35 55 55 100 Nature Communications | (2025) 16:1476 16 antibodies, cyclin A (Y193, abcam, 1/600, Opal 540), Cytokeratin (AE1/ AE3, Agilent DAKO, 1/300, Opal 480), Ki67 (SP6, abcam, 1/200, Opal 780), pRB ser807/811 (D20B12, Cell Signaling, 1/250, Opal 690), RB (4H1, Cell Signaling, 1/150, Opal 620) andMCM2 (RBT-MCM2, BioSB, 1/ 750, Opal 650).

    Cell Viability Assay:

    Article Title: CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities
    Article Snippet: The mIF panel consisted of the following antibodies (clone, company, and opal fluorophores): Cyclin D (SP4, Epredia, Opal 570), Cyclin E (EP435E, abcam, Opal 520), MCM2 (RBT-MCM2, Biosb, Opal Polaris 480), Pan Cytokeratin (AE1AE3, Agilent DAKO, Opal Polaris 780), pHH3 (Ser10, Millipore Sigma, Opal 620), pRB (Ser807/811, Cell Signaling, Opal 690).

    Article Title: Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle.
    Article Snippet: The MIF panel consisted of the following PHA-793887 Palbociclib Hesperadin Milciclib BMS-265246 Trametinib 0 20 40 60 80 100 0 20 40 60 80 100 ) Mn 052( 513X NI DMSO HCC1806 CCNE1 RB1 AMBRA1 DYRK1A PTEN -8 -6 -4 -2 0 2 4 6 8 10 0 5000 10000 15000 20000 N or m Z Rank_Synth HCC1806+Palbo (500 nM) CCNE1 CDK2 RB1 PTEN AMBRA1 DYRK1A -10 -5 0 5 10 15 0 5000 10000 15000 20000 Z mro N Rank_Synth MiaPaCa-2+Palbo (250 nM) Palbociclib Rapamycin BMS-265246 Barasertib SNS-032 Afatinib 0 20 40 60 80 100 120 0 20 40 60 80 100 120 IN X- ) Mn 0 01( 51 3 DMSO 1222 PHA-680632 Trametinib Palbociclib PD318088 PF-03814735 0 20 40 60 80 100 120 0 20 40 60 80 100 120 IN X- ) Mn 001( 513 DMSO 3226 20000 70000 120000 0 10 2 10 3 10 4 2N 4N 20000 70000 120000 0 10 1 10 2 10 3 10 4 2N 4N 20000 70000 120000 0 10 2 10 3 10 4 2N 4N 20000 70000 120000 0 10 1 10 2 10 3 10 4 2N 4N 20000 60000 100000 10 0 10 2 10 3 10 4 2N 4N 20000 60000 100000 0 10 1 10 2 10 3 10 4 2N 4N 20000 60000 100000 0 10 1 10 2 10 3 10 4 4N2N 20000 60000 100000 0 10 1 10 2 10 3 10 4 4N2N Palbo INX-315 Palbo+INX-315 PI Br dU -F IT C H C C 1806 M iaPaC a-2 DMSO - - + - - + + + - - + - - + + + Palbo (250 nM) INX-315 (250 nM) MiaPaCa-2-WT MiaPaCa-2-RB-del β Actin CDK1 Cyclin B1 Cyclin A pRB (S807/811) 40 35 55 55 100 Nature Communications | (2025) 16:1476 16 antibodies, cyclin A (Y193, abcam, 1/600, Opal 540), Cytokeratin (AE1/ AE3, Agilent DAKO, 1/300, Opal 480), Ki67 (SP6, abcam, 1/200, Opal 780), pRB ser807/811 (D20B12, Cell Signaling, 1/250, Opal 690), RB (4H1, Cell Signaling, 1/150, Opal 620) andMCM2 (RBT-MCM2, BioSB, 1/ 750, Opal 650).

    RNA Sequencing:

    Article Title: CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities
    Article Snippet: The mIF panel consisted of the following antibodies (clone, company, and opal fluorophores): Cyclin D (SP4, Epredia, Opal 570), Cyclin E (EP435E, abcam, Opal 520), MCM2 (RBT-MCM2, Biosb, Opal Polaris 480), Pan Cytokeratin (AE1AE3, Agilent DAKO, Opal Polaris 780), pHH3 (Ser10, Millipore Sigma, Opal 620), pRB (Ser807/811, Cell Signaling, Opal 690).

    Article Title: Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle.
    Article Snippet: The MIF panel consisted of the following PHA-793887 Palbociclib Hesperadin Milciclib BMS-265246 Trametinib 0 20 40 60 80 100 0 20 40 60 80 100 ) Mn 052( 513X NI DMSO HCC1806 CCNE1 RB1 AMBRA1 DYRK1A PTEN -8 -6 -4 -2 0 2 4 6 8 10 0 5000 10000 15000 20000 N or m Z Rank_Synth HCC1806+Palbo (500 nM) CCNE1 CDK2 RB1 PTEN AMBRA1 DYRK1A -10 -5 0 5 10 15 0 5000 10000 15000 20000 Z mro N Rank_Synth MiaPaCa-2+Palbo (250 nM) Palbociclib Rapamycin BMS-265246 Barasertib SNS-032 Afatinib 0 20 40 60 80 100 120 0 20 40 60 80 100 120 IN X- ) Mn 0 01( 51 3 DMSO 1222 PHA-680632 Trametinib Palbociclib PD318088 PF-03814735 0 20 40 60 80 100 120 0 20 40 60 80 100 120 IN X- ) Mn 001( 513 DMSO 3226 20000 70000 120000 0 10 2 10 3 10 4 2N 4N 20000 70000 120000 0 10 1 10 2 10 3 10 4 2N 4N 20000 70000 120000 0 10 2 10 3 10 4 2N 4N 20000 70000 120000 0 10 1 10 2 10 3 10 4 2N 4N 20000 60000 100000 10 0 10 2 10 3 10 4 2N 4N 20000 60000 100000 0 10 1 10 2 10 3 10 4 2N 4N 20000 60000 100000 0 10 1 10 2 10 3 10 4 4N2N 20000 60000 100000 0 10 1 10 2 10 3 10 4 4N2N Palbo INX-315 Palbo+INX-315 PI Br dU -F IT C H C C 1806 M iaPaC a-2 DMSO - - + - - + + + - - + - - + + + Palbo (250 nM) INX-315 (250 nM) MiaPaCa-2-WT MiaPaCa-2-RB-del β Actin CDK1 Cyclin B1 Cyclin A pRB (S807/811) 40 35 55 55 100 Nature Communications | (2025) 16:1476 16 antibodies, cyclin A (Y193, abcam, 1/600, Opal 540), Cytokeratin (AE1/ AE3, Agilent DAKO, 1/300, Opal 480), Ki67 (SP6, abcam, 1/200, Opal 780), pRB ser807/811 (D20B12, Cell Signaling, 1/250, Opal 690), RB (4H1, Cell Signaling, 1/150, Opal 620) andMCM2 (RBT-MCM2, BioSB, 1/ 750, Opal 650).

    Mutagenesis:

    Article Title: CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities
    Article Snippet: The mIF panel consisted of the following antibodies (clone, company, and opal fluorophores): Cyclin D (SP4, Epredia, Opal 570), Cyclin E (EP435E, abcam, Opal 520), MCM2 (RBT-MCM2, Biosb, Opal Polaris 480), Pan Cytokeratin (AE1AE3, Agilent DAKO, Opal Polaris 780), pHH3 (Ser10, Millipore Sigma, Opal 620), pRB (Ser807/811, Cell Signaling, Opal 690).

    Article Title: Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle.
    Article Snippet: The MIF panel consisted of the following PHA-793887 Palbociclib Hesperadin Milciclib BMS-265246 Trametinib 0 20 40 60 80 100 0 20 40 60 80 100 ) Mn 052( 513X NI DMSO HCC1806 CCNE1 RB1 AMBRA1 DYRK1A PTEN -8 -6 -4 -2 0 2 4 6 8 10 0 5000 10000 15000 20000 N or m Z Rank_Synth HCC1806+Palbo (500 nM) CCNE1 CDK2 RB1 PTEN AMBRA1 DYRK1A -10 -5 0 5 10 15 0 5000 10000 15000 20000 Z mro N Rank_Synth MiaPaCa-2+Palbo (250 nM) Palbociclib Rapamycin BMS-265246 Barasertib SNS-032 Afatinib 0 20 40 60 80 100 120 0 20 40 60 80 100 120 IN X- ) Mn 0 01( 51 3 DMSO 1222 PHA-680632 Trametinib Palbociclib PD318088 PF-03814735 0 20 40 60 80 100 120 0 20 40 60 80 100 120 IN X- ) Mn 001( 513 DMSO 3226 20000 70000 120000 0 10 2 10 3 10 4 2N 4N 20000 70000 120000 0 10 1 10 2 10 3 10 4 2N 4N 20000 70000 120000 0 10 2 10 3 10 4 2N 4N 20000 70000 120000 0 10 1 10 2 10 3 10 4 2N 4N 20000 60000 100000 10 0 10 2 10 3 10 4 2N 4N 20000 60000 100000 0 10 1 10 2 10 3 10 4 2N 4N 20000 60000 100000 0 10 1 10 2 10 3 10 4 4N2N 20000 60000 100000 0 10 1 10 2 10 3 10 4 4N2N Palbo INX-315 Palbo+INX-315 PI Br dU -F IT C H C C 1806 M iaPaC a-2 DMSO - - + - - + + + - - + - - + + + Palbo (250 nM) INX-315 (250 nM) MiaPaCa-2-WT MiaPaCa-2-RB-del β Actin CDK1 Cyclin B1 Cyclin A pRB (S807/811) 40 35 55 55 100 Nature Communications | (2025) 16:1476 16 antibodies, cyclin A (Y193, abcam, 1/600, Opal 540), Cytokeratin (AE1/ AE3, Agilent DAKO, 1/300, Opal 480), Ki67 (SP6, abcam, 1/200, Opal 780), pRB ser807/811 (D20B12, Cell Signaling, 1/250, Opal 690), RB (4H1, Cell Signaling, 1/150, Opal 620) andMCM2 (RBT-MCM2, BioSB, 1/ 750, Opal 650).

    Plasmid Preparation:

    Article Title: CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities
    Article Snippet: The mIF panel consisted of the following antibodies (clone, company, and opal fluorophores): Cyclin D (SP4, Epredia, Opal 570), Cyclin E (EP435E, abcam, Opal 520), MCM2 (RBT-MCM2, Biosb, Opal Polaris 480), Pan Cytokeratin (AE1AE3, Agilent DAKO, Opal Polaris 780), pHH3 (Ser10, Millipore Sigma, Opal 620), pRB (Ser807/811, Cell Signaling, Opal 690).

    Article Title: Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle.
    Article Snippet: The MIF panel consisted of the following PHA-793887 Palbociclib Hesperadin Milciclib BMS-265246 Trametinib 0 20 40 60 80 100 0 20 40 60 80 100 ) Mn 052( 513X NI DMSO HCC1806 CCNE1 RB1 AMBRA1 DYRK1A PTEN -8 -6 -4 -2 0 2 4 6 8 10 0 5000 10000 15000 20000 N or m Z Rank_Synth HCC1806+Palbo (500 nM) CCNE1 CDK2 RB1 PTEN AMBRA1 DYRK1A -10 -5 0 5 10 15 0 5000 10000 15000 20000 Z mro N Rank_Synth MiaPaCa-2+Palbo (250 nM) Palbociclib Rapamycin BMS-265246 Barasertib SNS-032 Afatinib 0 20 40 60 80 100 120 0 20 40 60 80 100 120 IN X- ) Mn 0 01( 51 3 DMSO 1222 PHA-680632 Trametinib Palbociclib PD318088 PF-03814735 0 20 40 60 80 100 120 0 20 40 60 80 100 120 IN X- ) Mn 001( 513 DMSO 3226 20000 70000 120000 0 10 2 10 3 10 4 2N 4N 20000 70000 120000 0 10 1 10 2 10 3 10 4 2N 4N 20000 70000 120000 0 10 2 10 3 10 4 2N 4N 20000 70000 120000 0 10 1 10 2 10 3 10 4 2N 4N 20000 60000 100000 10 0 10 2 10 3 10 4 2N 4N 20000 60000 100000 0 10 1 10 2 10 3 10 4 2N 4N 20000 60000 100000 0 10 1 10 2 10 3 10 4 4N2N 20000 60000 100000 0 10 1 10 2 10 3 10 4 4N2N Palbo INX-315 Palbo+INX-315 PI Br dU -F IT C H C C 1806 M iaPaC a-2 DMSO - - + - - + + + - - + - - + + + Palbo (250 nM) INX-315 (250 nM) MiaPaCa-2-WT MiaPaCa-2-RB-del β Actin CDK1 Cyclin B1 Cyclin A pRB (S807/811) 40 35 55 55 100 Nature Communications | (2025) 16:1476 16 antibodies, cyclin A (Y193, abcam, 1/600, Opal 540), Cytokeratin (AE1/ AE3, Agilent DAKO, 1/300, Opal 480), Ki67 (SP6, abcam, 1/200, Opal 780), pRB ser807/811 (D20B12, Cell Signaling, 1/250, Opal 690), RB (4H1, Cell Signaling, 1/150, Opal 620) andMCM2 (RBT-MCM2, BioSB, 1/ 750, Opal 650).

    Software:

    Article Title: CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities
    Article Snippet: The mIF panel consisted of the following antibodies (clone, company, and opal fluorophores): Cyclin D (SP4, Epredia, Opal 570), Cyclin E (EP435E, abcam, Opal 520), MCM2 (RBT-MCM2, Biosb, Opal Polaris 480), Pan Cytokeratin (AE1AE3, Agilent DAKO, Opal Polaris 780), pHH3 (Ser10, Millipore Sigma, Opal 620), pRB (Ser807/811, Cell Signaling, Opal 690).

    Article Title: Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle.
    Article Snippet: The MIF panel consisted of the following PHA-793887 Palbociclib Hesperadin Milciclib BMS-265246 Trametinib 0 20 40 60 80 100 0 20 40 60 80 100 ) Mn 052( 513X NI DMSO HCC1806 CCNE1 RB1 AMBRA1 DYRK1A PTEN -8 -6 -4 -2 0 2 4 6 8 10 0 5000 10000 15000 20000 N or m Z Rank_Synth HCC1806+Palbo (500 nM) CCNE1 CDK2 RB1 PTEN AMBRA1 DYRK1A -10 -5 0 5 10 15 0 5000 10000 15000 20000 Z mro N Rank_Synth MiaPaCa-2+Palbo (250 nM) Palbociclib Rapamycin BMS-265246 Barasertib SNS-032 Afatinib 0 20 40 60 80 100 120 0 20 40 60 80 100 120 IN X- ) Mn 0 01( 51 3 DMSO 1222 PHA-680632 Trametinib Palbociclib PD318088 PF-03814735 0 20 40 60 80 100 120 0 20 40 60 80 100 120 IN X- ) Mn 001( 513 DMSO 3226 20000 70000 120000 0 10 2 10 3 10 4 2N 4N 20000 70000 120000 0 10 1 10 2 10 3 10 4 2N 4N 20000 70000 120000 0 10 2 10 3 10 4 2N 4N 20000 70000 120000 0 10 1 10 2 10 3 10 4 2N 4N 20000 60000 100000 10 0 10 2 10 3 10 4 2N 4N 20000 60000 100000 0 10 1 10 2 10 3 10 4 2N 4N 20000 60000 100000 0 10 1 10 2 10 3 10 4 4N2N 20000 60000 100000 0 10 1 10 2 10 3 10 4 4N2N Palbo INX-315 Palbo+INX-315 PI Br dU -F IT C H C C 1806 M iaPaC a-2 DMSO - - + - - + + + - - + - - + + + Palbo (250 nM) INX-315 (250 nM) MiaPaCa-2-WT MiaPaCa-2-RB-del β Actin CDK1 Cyclin B1 Cyclin A pRB (S807/811) 40 35 55 55 100 Nature Communications | (2025) 16:1476 16 antibodies, cyclin A (Y193, abcam, 1/600, Opal 540), Cytokeratin (AE1/ AE3, Agilent DAKO, 1/300, Opal 480), Ki67 (SP6, abcam, 1/200, Opal 780), pRB ser807/811 (D20B12, Cell Signaling, 1/250, Opal 690), RB (4H1, Cell Signaling, 1/150, Opal 620) andMCM2 (RBT-MCM2, BioSB, 1/ 750, Opal 650).



    Similar Products

    mcm2 rbt-mcm2 antibody  (Bio SB Inc)
    90
    Bio SB Inc mcm2 rbt-mcm2 antibody
    Mcm2 Rbt Mcm2 Antibody, supplied by Bio SB Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mcm2+rbt-mcm2+antibody/mcm2+rbt+mcm2+antibody/pm39924553-464-344-346
    Average 90 stars, based on 1 article reviews
    mcm2 rbt-mcm2 antibody - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    rbt mcm2  (Cell Signaling Technology Inc)
    95
    Cell Signaling Technology Inc rbt mcm2
    Rbt Mcm2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mcm2+rbt-mcm2+antibody/MCM2+Antibody/pmc10499925__41698_2023_438_MOESM2_ESM-29-46-50
    Average 95 stars, based on 1 article reviews
    rbt mcm2 - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier

    Image Search Results